Two pathway inhibitors are showing promising results during early clinical trials, Gastroenterology and Endoscopy news reports.
Here's what you should know.
1. A team of researchers led by Brian Feagan, MD, are studying the use of risankizumab in 121 patients with Crohn's through a three part trial. During a 12-week period the patients were treated through a double-blind IV induction phase. Then in a 14-week period the patients received an open-label IV reinduction/washout period. Finally, the patients had a 26-week subcutaneous maintenance period.
Clinical remission ended at week 12 for the pooled dosing group.
2. Deep remission is possible through the use of the drug.
"Clinical response and rates of remission rose over time, and levels of C-reactive protein (CRP) and IL-22 progressively decreased," Dr. Feegan said.
4. Severine Vermeire, MD, and a team of researchers are studying the effects of filgotinib, an oral, JAK1 inhibitor.
5. The 20-week study enrolled 174 patients. "Anti–TNF-alpha–naive and anti–TNF-alpha nonresponders" were either given a 200 mg of filgotinib or a placebo for 10 weeks. After that they were given either a 200 or 100 mg dose of filgotinib or another placebo till the study's conclusion.
6. Dr. Vermeire reported higher Crohn's Diseases Activity Index remission rates for those receiving filgotinib, with higher clinical responses.
On an Inflammatory Bowel Disease Questionnaire, the filgotinib patients indicated significant improvements in quality of life.
More gastroenterology/endoscopy news:
267 patients at risk after Air Force Academy treats them with improperly processed endoscopy equipment: 5 things to know
AGA awards research fellowship to Kimberly Agbo: 3 things to know
As HCV medicine improves, a new market for organ transplants presents itself: 4 things to know